MASH Therapies: Approved Drug or Real-World Data

Nov 09 2025
Convention Center: Ballroom A, Level 3
5:00 PM - 6:30 PM

World Class Speakers

Naim Alkhouri, MD, FAASLD
Abstract Presenter

Naim Alkhouri, MD, FAASLD

Summit Clinical Research
Ludovic Saba, MD, MSc
Abstract Presenter

Ludovic Saba, MD, MSc

UT Southwestern Medical Center
Robert M Wilechansky, MD
Moderator

Robert M Wilechansky, MD

Oregon Health & Science University
Philip N Newsome, MD, PhD
Moderator

Philip N Newsome, MD, PhD

King's College London

Description

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Journey Maps

Presentations

5:30 PM - 5:45 PM
Apr 29 2026
Washington, D.C.

Two-year time course of biomarker and imaging responses in well-compensated MASH cirrhosis patients treated with resmetirom

Naim Alkhouri, MD, FAASLD , Abstract Presenter
MASLD
6:15 PM - 6:30 PM
Apr 29 2026
Washington, D.C.

Impact of Semaglutide on Cirrhosis and Complications in Patients with MASLD and Diabetes: A Retrospective Cohort Study

Ludovic Saba, MD, MSc , Abstract Presenter
MASLD

Objectives

  • Review efficacy and safety data from ongoing clinical trials of approved drugs for MASH, highlighting emerging evidence and remaining gaps.
  • Discuss challenges and insights from implementing approved MASH treatments, as well as weight loss medications, bariatric surgeries, and endoscopic procedures, in routine clinical practice. Presenters will also address issues related to patient selection and monitoring.